Abstract
Introduction Insomnia was widely distributed among the population, and it was a risk factor for many diseases. To evaluate the condition of usage of drugs in Chinese hospital of Longgang, Shenzhen, we carried this cross-sectional research. We extracted the information of drug usage, symptoms of patients by R software (version 4.0.2) from Hospital Information System (HIS). The research was registered in Chinese Clinical Trial Registry, ChiCTR2000040703.
Methods A retrospective, cross-sectional study was conducted in Shenzhen Hospital of Beijing University of Chinese Medicine (Long Gang). Insomnia patients from Jan 1, 2016 to Nov 10, 2020 were included to cross-sectional study. We analyzed the basic information, the condition of drug usage and the relation of symptoms and drug usage by R software (version 4.0.2).
Results Totally 9439 patients were included in the study. The average age of these patients was 45.81years (SD 13.97 years). Anxiety, dreaminess, dizzy, palpitation, headache, thirsty, weakness, chest distress, annoyance, abdominal distension, bad moods, difficulty falling asleep and bitter taste were core symptoms of insomnia. Totally 14256 times (67.65%) patients received drug prescription and more than one insomnia drug was administered in 8355 patients. The 10 most used drugs ranged from more to less were Estazolam(29.99%), Zaoren Anshen Capsule(15.50%), Oryzanol(14.82%), Diazepam(14.51%), Flupentixol and Melitracen(14.30%), Alprazolam(8.12%), Zolpidem Tartrate(5.29%), vitamin B6(4.76%), Sertraline(4.03%), Clonazepam(2.97%).
Conclusion The drug usage for insomnia in the Chinese medicine hospital in Long gang, Shenzhen were mainly included benzodiazepine, nonbenzodiazepine, Chinese patent medicines, anti-anxiety and anti-depression drugs, oryzanol and vitamin B6. The usage of Oryzanol and vitamin B6 should be abused in Chinese medicine hospital, and the usage of Chinese medicine should be more rigorous evaluated. The nonbenzodiazepine should be promoted and broader understood in Chinese medicine hospital in Longgang, Shenzhen.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Chinese Clinical Trial Registry, ChiCTR2000040703
Funding Statement
This work is funded by National Key Research and Development Plan(SQ2019YFC170218).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethic committee of Shenzhen Hospital of Beijing university of Chinese medicine，No.SZLDH2020LSYM-105
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Abbreviations
- HIS
- Hospital Information System
- BZRA
- Benzodiazepine receptor agonist
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos